A translational approach for NMDA receptor profiling as a vulnerability biomarker for depression and schizophrenia

The change in plasma arginine vasopressin concentration (P[AVP]) in response to osmotic stimulation (POsm) can be used as a biomarker for NMDA receptor signalling in schizophrenia and depression, distinguishing between these mental illnesses?
In response to hyperosmotic challenge, depressed subjects showed increased P[AVP] response in comparison with healthy control and schizophrenic subjects. 

Read the research paper:
http://onlinelibrary.wiley.com/doi/10.1113/EP086212/full

Comments

Popular posts from this blog

Bioinspired coating for medical devices repels blood and bacteria

Polycystic Ovary Syndrome Might Start in The Brain, Not The Ovaries!

Plain packets help smokers quit by killing brand identities